Patents Assigned to Inserm
  • Use of Xanthone Derivatives as a Medicament for Cancer
    Publication number: 20110263694
    Abstract: The invention relates to xanthone derivatives of formula (IA) or (IB) and their use for manufacturing a medicament for cancer, and in particular for chemotherapeutic resistant cancer. More particularly, the invention relates to compounds and compositions comprising such xanthone derivatives for the prevention and/or treatment for chronic leukemia and, for example, for chronic lymphocytic leukemia (CLL) or B-lymphoma.
    Type: Application
    Filed: April 6, 2009
    Publication date: October 27, 2011
    Applicants: MUSEUM NATIONAL D'HISTOIRE NATURELLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Jean-Pierre Kolb, Faouzia Menasria, Christian Billard, Michèle Meyer, Anatole Guy Azebaze, Augustin Ephrem Nkengfack
  • Biomarkers of Mineralocorticoid Receptor Activation
    Publication number: 20110257140
    Abstract: The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene.
    Type: Application
    Filed: October 21, 2009
    Publication date: October 20, 2011
    Applicant: INSERM (Institut National de la Sante et de la Rec herche Medicale)
    Inventors: Frederic Jaisser, Nicolette Farman, Yannis Sainte-Marie, Celine Latouche, Marja Steenman
  • NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS
    Publication number: 20110257176
    Abstract: A method for treating and/or ameliorating and/or preventing a disease or a disorder, the method comprising administering to an individual in need thereof at least one nitrogen heterocycle derivative of formula (I): The at least one nitrogen heterocycle derivative may also be used as a proteasome activity modulator in the manufacture of a pharmaceutical composition intended to prevent and/or treat a disease condition mediated by the proteasome activity.
    Type: Application
    Filed: April 4, 2011
    Publication date: October 20, 2011
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE RENNES 1, UNIVERSITE PARIS DIDEROT, UNIVERSITE PIERRE ET MARIE CURIE
    Inventors: Bruno VILLOUTREIX, Michele REBOUD-RAVAUX, Nicolas BASSE, Joelle VIDAL, Matthieu MONTES
  • Method for Detecting Soluble Amyloid Precursor Protein (APP) Alpha and/or Soluble APP Beta
    Publication number: 20110256559
    Abstract: The present invention relates to a method for detection or quantification of sAPP? and/or sAPP? in a sample and their use for diagnosing and/or monitoring a neurodegenerative disease in a subject in need thereof and kit for use in said method.
    Type: Application
    Filed: October 19, 2009
    Publication date: October 20, 2011
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Bernadette Allinquant, Christiane Rose
  • Methods and devices for delivering a therapeutic product to the ocular sphere of a subject
    Patent number: 8039445
    Abstract: The present invention relates, generally, to improved methods of delivering a biologically active agent, in particular a therapeutic or prophylactic nucleic acid, to the ocular sphere of a subject comprising administering said agent to the ciliary body tissue(s) or cells and/or to the extra-ocular muscle tissue or cells. More particularly, the invention relates to devices, their uses, notably in gene therapy, and to methods for treating pathologies of the ocular sphere by specific ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration of a therapeutic product and transfer thereof into the ocular tissue to be treated. This invention also relates to pharmaceutical compositions comprising the product in a form suitable for ciliary body tissue(s) or cells and/or extra-ocular muscle or cells administration, their preparation and uses.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: October 18, 2011
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Francine Behar-Cohen, David Benezra, Pascal Bigey, Carole Bloquel, Daniel Scherman
  • METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS
    Publication number: 20110244459
    Abstract: Methods for identifying ERBB2 (also named HER2) alteration in tumors, in particular cancer, based on the analysis of the expression of at least three genes of the ERBB2 amplicon located within less than one megabase on either side of ERBB2, and eventually of the gene corresponding to the Affymetrix probeset 234046_at (SEQ ID NO: 31), as well as a poynucleotide library useful for the molecular characterization of a cancer including polynucleotide sequences for detecting the genes, and a kit including the library.
    Type: Application
    Filed: December 9, 2009
    Publication date: October 6, 2011
    Applicants: IPSOGEN, INSERM-INSTITUT NATIONAL DE LA SANTE ET DE LA rECHERCHE MEDICALE, INSTITUT PAOLI-CALMETTES
    Inventors: Francois Bertucci, Rebecca Tagett, Sabrina Carpentier
  • Monoclonal Anti-Claudin 1 Antibodies for the Inhibition of Hepatitis C Virus Infection
    Publication number: 20110236347
    Abstract: The present invention provides monoclonal antibodies that specifically bind to the extracellular domain of human Claudin-1 on the cell surface, thereby inhibiting HCV entry into susceptible cells and preventing HCV infection of these cells; and hybridoma cell lines which produce such monoclonal antibodies. Also provided are reagents that comprise such antibodies, and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing HCV infection by administration of an inventive monoclonal antibody, or a pharmaceutical composition thereof are also described.
    Type: Application
    Filed: September 25, 2009
    Publication date: September 29, 2011
    Applicants: GENOVAC, UNIVERSITE DE STRASBOURG, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Thomas Baumert, Catherine Schuster, John Thompson, Fritz Grunert
  • Method, composition and kit for antigenic binding of norwalk-like viruses
    Patent number: 8026221
    Abstract: A method for detecting a Norwalk-Like Virus (NLV) in a biological sample, comprising the steps of: obtaining a biological sample suspected of containing a NLV; contacting the biological sample with at least one human histo-blood group antigen to allow formation of a complex of the NLV with the antigen; and detecting the antigen-NLV complex. The antigen-NLV complex can be detected by contacting the NLV-antigen complex with a NLV antibody that binds at an epitope of the NLV, and detecting the NLV antibody. The invention also includes a method for identifying compounds, and the compounds, that can inhibit the binding between a Norwalk-Like Virus (NLV) and a histo-blood group antigen.
    Type: Grant
    Filed: February 29, 2008
    Date of Patent: September 27, 2011
    Assignees: Children's Hospital Medical Center, INSERM
    Inventors: Xi Jiang, Jacques Le Pendu
  • USE OF P2X7 PATHWAY FOR ASSESSING THE SENSITIVITY OF A SUBJECT TO A CANCER TREATMENT
    Publication number: 20110229411
    Abstract: The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment.
    Type: Application
    Filed: November 27, 2008
    Publication date: September 22, 2011
    Applicants: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE PARIS-SUD XI
    Inventors: Lionel Apetoh, Antoine Tesniere, François Ghiringhelli, Laurence Zitvogel, Guido Kroemer
  • COMBINATION OF SPLA2 ACTIVITY AND OXPL/APOB CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT.
    Publication number: 20110229919
    Abstract: A method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, includes: measuring, in a sample obtained from the subject, at least two cardiovascular risk factors: a) sPLA2 activity and b) oxidized phospholipids on apolipoprotein B-100 particles (OxPL/apoB), combining the measurements, the combined value of sPLA2 activity and OxPL/apoB being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.
    Type: Application
    Filed: October 2, 2009
    Publication date: September 22, 2011
    Applicants: INSERM (INSTITUT NATIONAL DE LA SAINTE ET DE LA RECHERCHE MEDICALE), THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNIVERSITE PARIS DIDEROT-PARIS 7
    Inventors: Ziad Mallat, Alain TedguI, Sotirios Tsimikas, Joseph Witztum
  • Host Cell Kinases as Targets for Antiviral Therapies Against HCV Infection
    Publication number: 20110229484
    Abstract: The present invention provides several networks of cellular protein kinases as potential targets for medical intervention against hepatitis C virus (HCV) infection and HCV-related diseases and disorders in mammals, including humans. The invention relates to therapeutic protocols and pharmaceutical compositions designed to inhibit the activity of one or more of these protein kinases for the prevention and/or treatment of infections and diseases caused by HCV. The invention also relates to methods for the identification of kinase inhibitors that may be used to treat and/or prevent HCV infections and HCV-related diseases.
    Type: Application
    Filed: September 18, 2009
    Publication date: September 22, 2011
    Applicant: INSERM (Institut National de la Sant et de la Recherche Medicale)
    Inventors: Thomas Baumert, Joachim Lupberger
  • Inhibitors of MRP4 and Agents Stimulating MRP4 Activity for the Treatment of Cardiac Disorders
    Publication number: 20110218232
    Abstract: The invention relates to inhibitors of Multi drug Resistant Protein 4 (MRP4) for the treatment and/or the prevention of cardiac disorders, such as acute or chronic heart failure and cardiogenic shock. The invention also relates to agents stimulating MRP4 activity for the treatment and/or the prevention of cardiac hypertrophy.
    Type: Application
    Filed: July 17, 2009
    Publication date: September 8, 2011
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean-Sebastien Hulot, Anne-Marie Lompre, Yassine Sassi
  • Novel Melanoma Antigen Peptide and Uses Thereof
    Publication number: 20110212098
    Abstract: The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.
    Type: Application
    Filed: September 2, 2009
    Publication date: September 1, 2011
    Applicants: UNIVERSITE DE NANTES, CHU NANTES, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Nathalie Labarriere, Agnes Moreau-Aubry, Yann Godet
  • Antibodies directed against hepatitis C virus E1E2 complex, compositions of HCV particles, and pharmaceutical compositions
    Patent number: 8007792
    Abstract: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing them.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: August 30, 2011
    Assignees: INSERM, Biomerieux SA
    Inventors: Marie-Anne Petit, Colette Jolivet-Reynaud, Christian Trepo
  • Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
    Patent number: 8003773
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: August 23, 2011
    Assignees: Institut Pasteur, INSERM
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut, Kostas Kosmatopoulos, Stéphanie Graff-Dubois, Jeanne Menez-Jamet
  • POLY-HETEROARYL DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20110201648
    Abstract: The present invention relates to Penta-hexa-, hepta-, octa-, nona- and, deca-heteroaryl derivatives, comprising a combination of heterocycle 1 (Het-1)a and/or heterocycle 2 (Het-2)b and/or heterocycle 3 (Het-3)c and/or heterocycle 4 (Het-4)d of formulae I, II, III and IV respectively, the N-oxides, the pharmaceutically acceptable addition salts. The compounds claimed are suitable for the treatment of cancer.
    Type: Application
    Filed: November 2, 2009
    Publication date: August 18, 2011
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), MUSEUM NATIONAL D'HISTOIRE NATURELLE (MNHN)
    Inventors: Chi-hung Nguyen, Myriam Rouchon Dagois, Aurore Guedin-Beaurepaire, David Monchaud, Marie-Paule Teulade-Fichou, Jean-François Riou, Jean-Louis Mergny, David Grierson
  • Methods for Predicting the Response to Anti-Cancer Treatment with an Agonist of TLR7 or an Agonist of TLR8
    Publication number: 20110195923
    Abstract: The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of said patient.
    Type: Application
    Filed: August 14, 2009
    Publication date: August 11, 2011
    Applicant: INSERM (institiut National de la Sante et de la Re cherche medicale)
    Inventors: Julien Cherfils, Herve Fridman, Isabelle Cremer
  • TRANSGENIC ANIMALS AND METHODS OF MAKING RECOMBINANT ANTIBODIES
    Publication number: 20110185441
    Abstract: The present invention describes a means for obtaining cells which produce human, humanized or chimeric antibodies in commercially useful quantities. The invention permits high antibody producer cells to be selected and isolated from animals for use in culture to produce antibodies. The invention also provides methods for the affinity maturation of human, humanized or chimeric immunoglobulins.
    Type: Application
    Filed: April 8, 2011
    Publication date: July 28, 2011
    Applicants: INNATE PHARMA, S.A., INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: François Romagne, Bernard Malissen
  • Tr1 cells for use in atherosclerosis
    Patent number: 7985409
    Abstract: The present invention relates to a method of treating or preventing atherosclerosis comprising administering to a mammal in need of such a treatment a) an antigen which has been used to activate in vitro a Tri cell population originating from said mammal, and b) the TO cell population activated by said antigen, said TO cell population being obtained from a CD4+ T lymphocyte population of said mammal.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: July 26, 2011
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), TxCell
    Inventors: Hervé Groux, Alain Tedgui, Ziad Mallat, Valérie Brun
  • Method for predicting responsiveness to TNF? blocking agents
    Patent number: 7985549
    Abstract: The invention provides an in vitro method for predicting whether a patient would be responsive to a treatment with a TNF? blocking agent, which method comprises determining the expression level of eight genes in a biological sample of said patient, wherein said genes are EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 and RPS28. The invention further provides a DNA chip for performing such method.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 26, 2011
    Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean-Philippe Salier, Maryvonne Daveau, Anne-Christine Gauthier-Jauneau, Olivier Vittecoq, Xavier Le Loet, Alain Daragon, Othmane Mejjad, Thierry Lequerre